Karyopharm sets a course for the FDA with positive PhIIb multiple myeloma data
Investigators for Karyopharm Therapeutics $KPTI rolled out a positive set of data for their lead cancer drug selinexor bright and early Monday, touting a set of responses among patients who had run through a string of other treatments and mapping a clinical path that could point straight to the FDA’s door in 2018.
The drug was being tested among multiple myeloma patients who had proved resistant to a long slate of drugs, an indication of just how crowded MM has grown in recent years. Roughly one in 5 of the 78 evaluable patients demonstrated an objective response characterized as a partial response or a “very good” partial response.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
